Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

BMS, Dragonfly Working on Immune System-targeting Therapies for MS

Dragonfly Therapeutics and Bristol Myers Squibb (BMS) announced an expanded partnership focused on discovering and developing treatment candidates for multiple sclerosis (MS) and neuroinflammation targets. The companies have been working together in therapy research and development for cancer and autoimmune diseases using Dragonfly’s proprietary immunotherapy targeting…

$7.2M NIH Grant Supports Study of MS Diagnostic Biomarker

The National Institutes of Health (NIH) awarded a $7.2 million grant to a team led by Cleveland Clinic researchers that will study whether a new biomarker might more accurately diagnose multiple sclerosis (MS). Grant money will support a study in 400 adults suspected of having MS to determine if the…

World MS Day, May 30, Goes On … But Online

Despite the COVID-19 pandemic, there are many ways to participate in World MS Day 2020 on May 30, set aside to raise awareness about the neurodegenerative disorder that affects more than 2.3 million people globally. Organized by the MS International Federation (MSIF), the event brings together the global…

MedTech Breakthrough Cites RxMx and Roche for MS Patient App

For a comprehensive support app developed for multiple sclerosis (MS) patients, RxMx and Roche have won the Patient Engagement Innovation Award from Medtech Breakthrough. The fourth annual awards program recognized top health and medical technology products and companies. Healthcare company RxMx and pharmaceutical company Roche collaborated to produce…

Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland

After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines Consortium (SMC) for use in the country’s National Health System (NHS) to treat walking disabilities in adults with multiple sclerosis (MS). Scotland…

Two Data-sharing Initiatives Launched Regarding MS and COVID-19

Through two new initiatives, multiple sclerosis (MS) patients and their healthcare providers can contribute to a global effort to study and mitigate the impact of COVID-19 in MS and related disorders. The initiatives are aimed at helping clinicians identify the best way to manage the novel coronavirus in…

MS Society Spotlights Patient Stories for MS Awareness Week, March 8-14

The National Multiple Sclerosis Society (NMSS) is marking Multiple Sclerosis Awareness Week, March 8-14, by sharing patients’ stories and encouraging participation in fundraising and advocacy efforts. Each year, a week is set aside to heighten awareness of multiple sclerosis (MS), a neurodegenerative disorder that affects nearly 1 million people in…

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award

For its promising investigational therapeutic approach to neurodegenerative diseases, including progressive multiple sclerosis (MS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The…

Sara Loud to Lead Accelerated Cure Project for MS as New CEO

Leadership changes at the Accelerated Cure Project (ACP) for Multiple Sclerosis aim to enhance the nonprofit patient-founded organization’s research focus. Robert McBurney has stepped down as president and CEO after eight years to become ACP’s first chief research officer. He will continue in the position of research lead for the…

Michigan’s Memorial Healthcare First in US to Test NfL in MS Patients

Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis announced it will become the first U.S. hospital to test a nerve cell-derived component known as neurofilament light chain (NfL) in multiple sclerosis (MS) patients. Led by the Owosso, Michigan, hospital’s chief of neurology and MS director, Rany Aburashed, DO,…

Corrona Expands MS Patient Registry to Include Genentech

Corrona has expanded its collaborative multiple sclerosis (MS) U.S. patient registry to include Genentech, the first pharmaceutical company to participate. Established in 2017, the Corrona MS Registry is a real-world U.S.-based registry, developed in collaboration with the National MS Society. Its goal is to help guide treatment decisions based on…

Artists and MSAA Mark 10 Years of Showcasing Original Works

A bird in flight, a field of flowers, a dog surrounded by butterflies, a portrait of a toddler — they’re all part of the artwork by the multiple sclerosis (MS) community done for a Multiple Sclerosis Association of America (MSAA) showcasing program, now marking its 10th year. Through its…